Logo Cegat neu 2021

CeGaT GmbH

CeGaT is a provider of genetic diagnostics and NGS services.

CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

Founded in 2009 in Tübingen, Germany, the company combines stateof-the-art sequencing technology with medical expertise - with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumor analysis. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.

The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT‘s laboratory is accredited according to CAP/CLIA and DIN EN ISO 15189, and thus meets the highest international standards. In order to obtain first-class results, all processes are carried out in-house under scientific supervision.

Category Biotechnology
Working areas Biotechnology, Diagnostics, Genetics, Oncology, Sequencing
Year of foundation
2009
Employees
> 100

News

09.04.2024

CeGaT has multiple reasons to celebrate

Tübingen, April 9, 2024 – CeGaT, a global provider of genetic diagnostics and sequencing services based in Tübingen, Germany, is celebrating several events: CeGaT turns 15 years…

16.11.2023

CeGaT Revolutionizes Exome Diagnostics with Genome-wide CNV Analysis

Tübingen: CeGaT, a global provider of genetic diagnostics and sequencing services, presents an innovation in exome diagnostics: With the integration of a CNV backbone, it is now…

01.06.2023

CeGaT and Twist Bioscience Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

Tübingen –  CeGaT GmbH, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, and Twist Bioscience Corporation (NASDAQ: TWST), a…

01.06.2023

CeGaT and Twist Bioscience Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

RNA fusions can be used as biomarkers to identify cancer sub-types and monitor for residual disease